Stock chart
Analyses on Matricelf (4)
- March 24, 2026March 24, 2026
- Follow-up
Matricelf: What the Ramot Extension Really Adds and How Much Upside Survives the Royalty Stack
The Ramot extension through 2028, and conditionally through 2030, clearly expanded Matricelf’s strategic optionality, but the disclosed royalty structure, payment floors, and sublicense economics, together with the Parkinson route in which the parent is expected to own only 25%…
- Follow-up
Matricelf: How Much Runway Did the 2025 Financing Buy, and How Much Dilution Still Sits Ahead?
Matricelf’s October 2025 financing bought roughly a year of room, but at the cost of a heavy derivative liability, dilution that has already started, and an explicit acknowledgement that the Nasdaq and FIH path still needs fresh capital.
- Follow-up
Matricelf: Does the Ichilov-to-Sheba Switch Actually Pull FIH Closer?
The Ichilov-to-Sheba switch improves Matricelf's execution odds in an autologous manufacturing model, but at this stage it preserves the FIH path more than it accelerates it.
Matricelf 2025: More Cash, Later First-in-Human, and a Smaller Market Story
Matricelf moved in 2025 from an abstract preclinical platform toward a more structured FIH path, but the real bottleneck is no longer just science. It is the combined test of funding, GMP execution, and timing discipline.
